BR112022019202A2 - Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal - Google Patents

Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal

Info

Publication number
BR112022019202A2
BR112022019202A2 BR112022019202A BR112022019202A BR112022019202A2 BR 112022019202 A2 BR112022019202 A2 BR 112022019202A2 BR 112022019202 A BR112022019202 A BR 112022019202A BR 112022019202 A BR112022019202 A BR 112022019202A BR 112022019202 A2 BR112022019202 A2 BR 112022019202A2
Authority
BR
Brazil
Prior art keywords
animal
composition
oligopeptide
promoting growth
human
Prior art date
Application number
BR112022019202A
Other languages
English (en)
Inventor
Disston Nalle Horace Jr
Kaltenboeck Bernhard
Original Assignee
Nutrivert Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrivert Llc filed Critical Nutrivert Llc
Publication of BR112022019202A2 publication Critical patent/BR112022019202A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

OLIGOPEPTÍDEO, COMPOSIÇÃO FARMACÊUTICA, COMPOSIÇÃO, E, USOS DE PELO MENOS UM OLIGOPEPTÍDEO E DE UMA COMPOSIÇÃO. Composições de matéria e métodos para reduzir inflamação em vertebrados e para promover crescimento e conversão de alimento em animais pela administração de uma quantidade eficaz de uma composição contendo uma molécula de imagem em espelho (enantiômero) de um derivado de dipeptídeo de muramila lipofílico (MDP) que não contém a porção de N-acetilglucosamina do MDP (isto é, um dipeptídeo de desmuramila).
BR112022019202A 2020-03-26 2021-03-25 Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal BR112022019202A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000364P 2020-03-26 2020-03-26
PCT/US2021/024142 WO2021195372A1 (en) 2020-03-26 2021-03-25 Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity

Publications (1)

Publication Number Publication Date
BR112022019202A2 true BR112022019202A2 (pt) 2022-11-08

Family

ID=77892334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019202A BR112022019202A2 (pt) 2020-03-26 2021-03-25 Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal

Country Status (11)

Country Link
US (1) US20230174577A1 (pt)
EP (1) EP4126040A4 (pt)
JP (1) JP2023518973A (pt)
KR (1) KR20220158773A (pt)
CN (1) CN115605226A (pt)
AU (1) AU2021241625A1 (pt)
BR (1) BR112022019202A2 (pt)
CA (1) CA3172936A1 (pt)
MX (1) MX2022011751A (pt)
WO (1) WO2021195372A1 (pt)
ZA (1) ZA202210586B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
US10844377B2 (en) 2017-06-23 2020-11-24 University Of Massachusetts Two-tailed self-delivering siRNA
JP2022528840A (ja) 2019-03-26 2022-06-16 ユニバーシティ・オブ・マサチューセッツ 安定性が増加した修飾オリゴヌクレオチド
MX2022001710A (es) 2019-08-09 2022-05-10 Univ Massachusetts Oligonucleótidos modificados químicamente dirigidos a los snp.
WO2024102639A1 (en) * 2022-11-08 2024-05-16 The Scripps Research Institute N-arylpyrazole nod2 agonists as promoters of immune checkpoint inhibitor therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301789A (es) * 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
EP2975046A1 (en) * 2014-07-16 2016-01-20 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Novel compounds
WO2017098529A1 (en) * 2015-12-10 2017-06-15 Bharat Biotech International Limited Novel muramyl peptide derivative compound, synthesis and uses thereof
TWI634902B (zh) * 2017-10-28 2018-09-11 醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 Use of glucosamine peptide compounds for the treatment of abnormal liver metabolism

Also Published As

Publication number Publication date
US20230174577A1 (en) 2023-06-08
ZA202210586B (en) 2023-05-31
JP2023518973A (ja) 2023-05-09
MX2022011751A (es) 2022-12-02
CN115605226A (zh) 2023-01-13
EP4126040A1 (en) 2023-02-08
KR20220158773A (ko) 2022-12-01
WO2021195372A1 (en) 2021-09-30
EP4126040A4 (en) 2024-04-24
CA3172936A1 (en) 2021-09-30
AU2021241625A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
BR112022019202A2 (pt) Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal
BR112018072064B8 (pt) Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
ES2162586B1 (es) Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
CA2260265A1 (fr) Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
PT979224E (pt) Composicoes solidas adequadas para administracao oral compostas por l-carnitina ou alcanoil-l-carnitina fuarato de magnesio
DK0973515T3 (da) Faste sammensætninger, der er egnet til oral indgivelse, hvilke sammensætninger omfatter et alkanoyl-L-carnitinmagnesiumcitrat
ES2166596T3 (es) Composiciones solidas apropiadas para administracion oral que comprende l-carnitina y tartrato de magnesio de alcanoil-l-carnitina.
CL2020002800A1 (es) Composiciones y mètodos para alimentar mamìferos
PT971880E (pt) Composicoes solidas adequadas para administracao oral compreendendo sais nao-hidroscopicos de l-carnitina e alcanoil-l-carnitina com acido 2-aminoetanossulfonico
BRPI0419209A2 (pt) mÉtodo de aumentar a palatabilidade de um produto de raÇço extrusado para animais de estimaÇço, composiÇço intensificadora da palatabilidade para raÇço de animal de estimaÇço extrusada, e, composiÇço de raÇço extrusada para animal de estimaÇço
BR9808908A (pt) Composições sólidas adequadas para administração oral que compreendem l-carnitina ou tartarato de alcanoil-l-carnitina colina
RU2013154562A (ru) Способы и композиции для сохранения безжировой массы тела в процессе похудения
RU2008114890A (ru) Состав, применямый при стрессе у людей и в ветеринарии
BRPI0415111A (pt) composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
PA8567601A1 (es) Sal agonista del receptor b3-adrenergico, sus formulaciones y sus usos